Fetal and neonatal exposure to nicotine in Wistar rats results in increased beta cell apoptosis at birth and postnatal endocrine and metabolic changes associated with type 2 diabetes
- First Online:
- Cite this article as:
- Holloway, A.C., Lim, G.E., Petrik, J.J. et al. Diabetologia (2005) 48: 2661. doi:10.1007/s00125-005-0022-5
- 660 Downloads
Epidemiological studies report an increased risk of obesity and type 2 diabetes in children born to women who smoked during pregnancy. This study examines the effect of fetal and neonatal exposure to nicotine, the major addictive component of cigarettes, on postnatal growth, adiposity and glucose homeostasis.
Female Wistar rats were given either saline (vehicle) or nicotine (1 mg kg−1 day−1) during pregnancy and lactation. Serum and pancreas tissue were collected from the infant rats at birth. Postnatal growth was assessed weekly until the rats reached 26 weeks of age and glucose homeostasis was examined by OGTTs performed at 7 and 26 weeks of age.
Exposure to nicotine resulted in increased postnatal growth and adiposity. Nicotine exposure also resulted in dysglycaemia at 7 and 26 weeks of age. Serum insulin concentrations were decreased in the pups exposed to nicotine at birth. This was associated with increased beta cell apoptosis (pups of saline-treated mothers 8.8±1.21% apoptotic beta cells; pups of nicotine-treated mothers 27.8±3.1% apoptotic beta cells).
Fetal and neonatal exposure to nicotine results in metabolic changes in the offspring that are consistent with obesity and type 2 diabetes. We propose that these metabolic changes may be a consequence of the initial insult to the beta cell during fetal life and that this animal model has many characteristics of diabetes in humans.
KeywordsAdult-onset diseaseBeta cell apoptosisDyslipidaemiaGlucose homeostasisNicotineType 2 diabetes
postnatal day 1
postnatal day 21
terminal deoxynucleotidyl transferase mediated dUTP nick end labelling
The intrauterine environment is emerging as an important determinant of chronic adult diseases including diabetes, obesity and cardiovascular disease. A variety of physiological stresses during pregnancy are thought to contribute to the development of adult disease. One such stress is maternal cigarette smoking. Recent epidemiological studies have shown a strong relationship between maternal smoking and subsequent obesity, hypertension and type 2 diabetes in the offspring [1–8]. Although many women report a desire to quit smoking while pregnant, nicotine dependence is a significant element of most patients’ smoking behaviour . For this reason nicotine replacement therapy has been widely developed as a pharmacotherapy of smoking cessation, and is considered to be of benefit for pregnant women who are highly dependent and have been unable to quit smoking by other means [9–11]. However, very few studies have studied the safety of nicotine replacement during pregnancy .
In animal studies, prenatal exposure to nicotine alone was sufficient to produce reduced birthweight and increased body weight post-natally  and significantly higher levels of body fat in fetuses of nicotine-exposed dams at gestation day 20 (term 22 days) . The fact that these are risk factors for future obesity and dysglycaemia  suggests that prenatal nicotine exposure may have lifelong metabolic effects that begin at birth. The effect of fetal and neonatal nicotine exposure on growth, weight, adiposity, glucose homeostasis and beta cell area is reported in this study.
Subjects, materials and methods
Maintenance and treatment of animals
All animal experiments were approved by the Animal Research Ethics Board at McMaster University, in accordance with the guidelines of the Canadian Council for Animal Care. Nulliparous 200–250-g female Wistar rats (Harlan, Indianapolis, IN, USA) were maintained under controlled lighting (12:12 h light:dark) and temperature (22°C) with free access to food and water. Two weeks prior to mating the dams were randomly assigned to receive either saline (vehicle) or nicotine (n=4 per group). Dams were injected s.c. with 1 mg·kg−1·day−1 nicotine bitartrate (Sigma Aldrich, St Louis, MO, USA) or saline for 14 days prior to mating, and during pregnancy until weaning. Pups were weighed after birth (postnatal day 1; PND1) and the litters were culled to eight at birth, retaining males in preference to assure uniformity of litter size between treated and control litters. Trunk blood was collected from culled animals and allowed to clot at 4°C, then centrifuged and stored at −80°C until analysis for insulin and glucose concentrations. Serum glucose concentrations were measured using a commercially available kit for the glucose oxidase method (Pointe Scientific, Canton, MI, USA), and insulin levels were measured on an ultra-sensitive rat insulin ELISA (Crystal Chem, Downers Grove, IL, USA). The insulin ELISA kit had a detection limit of 5 pg/ml with intra- and interassay variabilities of 5.5 and 4.8%, respectively. After weaning at postnatal day 21 (PND21), male offspring were selected randomly and caged as sibling pairs. Pups were weighed weekly from PND1 until 26 weeks of age. Fasting serum samples were collected at 7, 15 and 26 weeks and were analysed for triglyceride concentrations using a commercially available assay (Pointe Scientific).
Glucose tolerance tests
Glucose tolerance was serially investigated in nicotine-exposed and control rats at 7 and 26 weeks (n=16 per group). Serum concentrations of insulin and glucose were measured in saphenous vein samples obtained after food deprivation at 0 (09:00 hours), 30 and 120 min after rats were given 2 g/kg glucose (Sigma-Aldrich) in water by gavage. Blood samples were allowed to clot at 4°C, then centrifuged and stored at −80°C until used for measurement of serum glucose and insulin concentrations as described above.
Immunohistochemistry: beta cell area
To assess whether nicotine exposure can alter pancreas development, pancreas tissue was removed from all culled pups at birth (PND1). The pancreas from each animal was weighed and then fixed by immersion in 10% neutral-buffered formalin (EM Science, Gibbstown, NJ, USA) at 4°C overnight, washed in PBS and embedded in paraffin. Immunohistochemical detection of insulin was performed on 5-μm sections of neonatal pancreatic tissue (PND1; n=10 per group). Tissue sections were deparaffinised in xylene, rehydrated and washed in PBS. After quenching in methanol of endogenous peroxidase activity, antigen retrieval was performed in 10 mmol/l citrate buffer (pH 3.0) followed by incubation with 10% normal goat serum and 1% BSA. Sections were then incubated overnight at 4°C with the primary antibody, a polyclonal, guinea-pig anti-human insulin antibody (1:150 dilution) (DakoCytomation, Carpinteria, CA, USA) which has been shown by the manufacturer to cross-react with rat insulin peptides. Sections were then washed in PBS, and immunostaining was identified using the Vectastain kit (Vector Laboratories, Burlinghame, CA, USA) with diaminobenzadine as the chromogen. Tissue sections were counterstained, dehydrated and mounted with Permount (Fisher Scientific, Fair Lawn, NJ, USA). Control sections were incubated with 1% BSA in PBS in place of the primary antibody. All measurements were performed at 10× magnification, and the whole pancreas was analysed. Immunopositive cells were identified and the beta cell area was calculated as a percentage of the total area of the section using integrated morphometry software (Metamorph, Universal Imaging, Downington PA, USA). At least 25 fields were counted per animal.
Immunohistochemistry: detection of beta cell apoptosis
Histological sections of pancreas from animals at PND1 were processed and fixed as described above. Apoptotic islet cells were detected using a terminal deoxynucleotidyl transferase mediated dUTP nick end labelling (TUNEL) kit (Roche Applied Science, Laval, PQ, Canada) following the manufacturer’s protocol. Briefly, after fixation, tissues and cells were made permeable in 0.1% Triton X-100 for 15 min, washed in PBS, and incubated with the fluorescein isothiocyanate-conjugated TUNEL enzyme for 60 min to detect DNA fragmentation. Nuclei were counterstained with propidium iodide and images were obtained on an Olympus BX-61 microscope. For analysis, ten fields of view at 250× magnification were counted for each animal (n=5 animals per group). To evaluate the percentage of beta cells that were apoptotic in the pancreas islets, pancreas tissue from pups at PND1 was processed for double-label immunofluorescence. For double-label immunofluorescence, sections were initially analysed on an apoptosis detection kit, as described above. Following staining for fragmented DNA, sections were incubated overnight at 4°C with an anti-insulin antibody (DakoCytomation, Carpinteria, CA, USA; 1:150). A Texas Red-conjugated anti-mouse antibody (Vector Laboratories, Burlington, ON, USA; 1:100 dilution) was used for detection. Nuclei were counterstained with propidium iodide or DAPI and images of the specimens were obtained on an Olympus BX-61 fluorescent microscope.
All statistical analyses were performed using SigmaStat (v.2.03, SPSS, Chicago, IL, USA), and t-test or analyses of variance (ANOVA) followed by appropriate post-hoc tests when significance was indicated by the ANOVA (α=0.05). Data were tested for normality as well as equal variance, and when normality or variance tests failed, data were analysed using Mann–Whitney rank sum test or Kruskal–Wallis one-way ANOVA on ranks. Area under the curve for the total glucose response following the glucose tolerance test and postnatal growth was assessed using the trapezoidal rule.
Birthweight was reduced in rats that were exposed to nicotine in utero (saline 6.54±0.099 g, nicotine 6.29±0.056 g, n=47 and 59, p<0.05) whereas the litter size, sex ratio and gestational length were unaffected (data not shown).
Postnatal growth and adiposity
Effect of in utero exposure to nicotine on serum hormone concentrations, pancreatic beta cell area and islet apoptosis at PND1
Beta cell area (% of total)
Islet apoptosis (% of total)
At 26 weeks there was no significant difference in basal fasting serum glucose levels between saline- and nicotine-exposed offspring, but the fasting insulin concentrations were significantly elevated in the nicotine-exposed offspring. Nicotine-exposed rats exhibited impaired glucose homeostasis and a significantly higher insulin response to the glucose challenge (Fig. 2).
Beta cell area and apoptosis
To assess whether the differences in serum insulin levels at PND1 were a result of an altered number of beta cells or increased beta cell death, we evaluated both the beta cell area and the percentage of apoptotic beta cells in the pancreas at PND1. There was no significant effect of treatment on beta cell area; however, the offspring of the nicotine-exposed dams had significantly higher (p<0.001) levels of apoptosis in the pancreatic islet cells compared to the offspring of the saline-exposed dams (Table 1). To confirm that the apoptotic islet cells were in fact insulin-secreting cells, pancreatic tissue from animals at PND1 was dual-labelled with insulin and TUNEL staining. In the pancreas tissue from control offspring there were 8.8±1.21% TUNEL/insulin-positive beta cells and in the nicotine-exposed offspring there were 27.8±3.1% TUNEL/insulin-positive beta cells (p<0.001).
Recent epidemiological studies have shown that the offspring of women who smoke during pregnancy have an increased risk of developing obesity, hypertension and type 2 diabetes [1–8]. The mechanism(s) underlying these associations are unknown. The results from this study demonstrate for the first time that nicotine exposure alone, at concentrations which are representative of human exposure [17, 18], during pregnancy and lactation results in endocrine and metabolic changes in the offspring that are consistent with the disturbed glucose metabolism that may lead to type 2 diabetes.
In the present study we have shown that fetal and neonatal exposure to nicotine results in impaired glucose homeostasis in response to a glucose challenge prior to a measurable difference in body weight (7 weeks of age), suggesting that in this model the metabolic changes associated with the onset of type 2 diabetes precede obesity. Furthermore, we found that nicotine exposure during the fetal period alone resulted in a significant reduction in serum insulin concentrations at PND1 in association with a significant increase in the number of apoptotic islet cells. We therefore propose that the nicotine-induced damage to the beta cell during fetal development results in permanent changes in pancreatic function, which are evident as impaired glycaemic control at 7 weeks of age and which persist until adulthood (26 weeks of age).
Similarly, other in utero insults including glucocorticoid administration, uteroplacental insufficiency and fetal undernutrition have been shown to result in long-lasting functional deficiencies in the endocrine pancreas [19–22]. At 26 weeks of age nicotine-exposed offspring exhibit dysglycaemia and increased serum insulin concentrations. The elevated insulin concentrations at 26 weeks of age are probably a result of the dysglycaemia and/or impaired sensitivity to insulin, in a similar manner to glucose intolerance in humans. Because dysglycaemia precedes obesity in this model, we speculate that the metabolic changes associated with type 2 diabetes are not caused by obesity, but that this initial underlying beta cell defect could represent a common antecedent for the postnatal obesity and the dysglycaemia observed by us.
We propose that nicotine acts directly at the fetal beta cell to cause apoptosis, possibly by increasing oxidative stress at that location. In adult rats, nicotine exposure has been shown to produce oxidative tissue injuries in vivo [23, 24] and can induce oxidative stress in pancreatic tissue in vitro . Oxidative stress has been shown to decrease insulin secretion and to increase apoptosis in beta cells [reviewed in Ref. 26], results which are reflected by the decrease in serum insulin concentrations and increased beta cell apoptosis observed at PND1 in this study. Alternatively nicotine may act directly at the nicotinic receptors on the beta cell to inhibit insulin secretion, as has been demonstrated in isolated rat islets in vitro . Further studies will be required to address this question and to determine the specific developmental stages that are sensitive to nicotine exposure.
Results from this study have shown that (1) nicotine, at levels that are relevant for human exposure, results in postnatal obesity and impaired glucose homeostasis and (2) that these postnatal changes may be a result of an underlying defect in the pancreatic beta cell. On the basis of our results, we propose that the long-term postnatal health consequences of nicotine exposure warrant further investigation. Our results also raise concerns regarding the safety of nicotine replacement therapy during pregnancy and lactation.
This work was supported by an operating grant from the Canadian Institutes of Health Research in Nutrition, Metabolism and Diabetes to A. C. Holloway and K. M. Morrison (MOP 69025), and a fellowship from the Heart and Stroke Foundation to K. M. Morrison. H. C. Gerstein holds the Population Health Institute Chair in Diabetes Research (sponsored by Aventis). We thank Ms Sandra Stals, Ms Lisa Kellenberger and the staff of the McMaster University Central Animal Facility for their excellent technical assistance.